| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sudarshanpharma.com | |
| Market Cap | 199.75 Cr. | |
| Enterprise Value(EV) | 222.13 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.92 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 28.39 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 37.72 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 41.96 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.98 | Calculated using Price: 83.00 |
| Dividend Yield | 0.36 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.41 Cr. | 24,065,887 Shares |
| FaceValue | 10 | |
| About Sudarshan Pharma Industries Ltd. | ||
| The company is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It outsource its manufacturing facility, deal in Import and Exports, indenting and Supply in Specialty chemicals, API & its intermediate. As per the clients need and requirement, it provide order and get them manufactured from various suppliers in India and abroad regularly. | ||
| 1 Day |
|
|
| 1 Week |
|
-3.77% |
| 1 Month |
|
+1.84% |
| 3 Month |
|
+26.70% |
| 6 Month |
|
+37.28% |
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 3 years | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 11.87 | 20.08 | 10.76 | |
| Return on Capital Employed (%) | 13.01 | 18.67 | 15.25 | |
| Return on Assets (%) | 2.69 | 4.43 | 3.80 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Shh. Funds | 23 | 30 | 101 | |
| Non Curr. Liab. | 5 | 5 | 13 | |
| Curr. Liab. | 71 | 103 | 118 | |
| Minority Int. | 0 | |||
| Equity & Liab. | 99 | 138 | 232 | |
| Non Curr. Assets | 12 | 8 | 34 | |
| Curr. Assets | 88 | 130 | 199 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 99 | 138 | 232 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 193 | 357 | 461 | |
| Other Income | 0 | 0 | 1 | |
| Total Income | 194 | 358 | 462 | |
| Total Expenditure | -186 | -346 | -447 | |
| PBIDT | 8 | 11 | 16 | |
| Interest | -3 | -3 | -5 | |
| Depreciation | -1 | -1 | -1 | |
| Taxation | -1 | -2 | -2 | |
| Exceptional Items | ||||
| PAT | 3 | 5 | 7 | |
| Minority Interest | ||||
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | 3 | 5 | 7 | |
| Adjusted EPS | 3 | 5 | 3 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | -4 | -29 | |
| Cash Fr. Inv. | -1 | -1 | -26 | |
| Cash Fr. Finan. | -1 | 4 | 66 | |
| Net Change | 0 | -1 | 11 | |
| Cash & Cash Eqvt | 1 | 0 | 12 |
|
Fri, 15 Sep 2023
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Resignation of Mr. Dharam Jilka from the position Chief Financial Officer (KMP) of the Company. |
|
Fri, 15 Sep 2023
Announcement under Regulation 30 (LODR)-Change in Management Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Resignation of Mr. Dharam Jilka from the position of Chief Financial Officer (KMP) of the Company. |
|
Mon, 04 Sep 2023
Announcement under Regulation 30 (LODR)-Investor Presentation Sudarshan Pharma Industries Limited hereby itimates the stock Exchange about the Investor Presentation of the Company. |
| Wed, 27 Sep 2023 |
High Delivery Percentage
|
Close Crossing Last Month Close From Below
|
Opening at High
|
Close Within 52 Week High Zone
|
Close Below Last Week Low
|
Equities
M.F.
Sectors
StockEdge Social